Accepted answer
Read ATTAIN-1 by arm, because the arm is the unit of randomisation and every figure worth quoting is defined at that level. A programme that randomised several dose levels reports each one separately, with its own sample size and its own interval, and the pooled number that circulates afterwards describes a group nobody was assigned to. Take the primary publication and its supplementary tables rather than a summary of them: one is organised by arm, the other by whichever figure was largest. And check the estimand — what happened to everyone assigned, or what happens to those who kept taking it — because the two answer different questions and are routinely quoted as though they were one.
The short version: glucose-dependent insulinotropic action, glucagon suppression, delayed gastric emptying and central appetite effects, from one receptor in four places.
Gastric emptying delay attenuates with continued exposure for long-acting agents through receptor desensitisation, which is why the early nausea usually settles while the appetite effect persists.
What each test answers
| Test | Answers | Does NOT answer |
|---|
| RP-HPLC, area % | What fraction of detected material is the target | How much target is present |
| Quantified content | Milligrams of peptide per vial | What the impurities are |
| ESI-MS identity | Whether the molecular weight matches | Purity, or isomeric substitution |
| Peptide mapping | Sequence, localised to a fragment | Quantity |
| Karl Fischer | Water content of the solid | Solvent content |
| LAL endotoxin | Pyrogen load in EU/mg | Sterility |
| Sterility test | Growth in defined media over 14 days | Endotoxin, or bioburden count |
Put another way, central effects reach the arcuate nucleus and the area postrema, regions with an incomplete blood-brain barrier. That anatomy is why a large peptide can act centrally at all, and it also explains the nausea, since the area postrema is the chemoreceptor trigger zone.
Structural work on the receptor by cryo-electron microscopy has resolved the agonist-bound active state and is the basis for current structure-guided design in this class.
Research-use material is not approved for human use, and mechanism is not a safety argument.
Glucose-dependence is the property to remember; it explains the safety profile on its own.
4Small correction: the oral and injectable milligrams are not comparable, as stated above. – e_dziedzic 9 days ago 3Is the fusion-protein point relevant to what is actually sold as research material? – Dr_Jonas_Halvorsen 9 months ago add a comment